Table 3.
Data of two major TMVR registries
| Registry | Yoon et al. 2019a | Guerrero et al. 2020b | ||||
|---|---|---|---|---|---|---|
| Number of patients | 521 | 903 | ||||
| -ViV | 322 | 680 | ||||
| -ViR | 141 | 123 | ||||
| -ViMAC | 58 | 100 | ||||
| Age | 73 ± 12 | 75 [67-82] | ||||
| STS-PROM (%) | 9 ± 7 | 10 [7-16] | ||||
| Sapien valve (%) | 90 | 96 | ||||
| Access | ||||||
| -Transseptal (%) | 40 | 43 | ||||
| -Transapical (%) | 60 | 45 | ||||
| Outcomes | ViV (%) | ViR (%) | ViMAC (%) | ViV (%) | ViR (%) | ViMAC (%) |
| Technical success* | 94 | 81 | 62 | 91 | 83 | 74 |
| LVOTO** | 2 | 5 | 40 | 1 | 5 | 10 |
| Conversion to surgery | 1 | 3 | 9 | 1 | 2 | 2 |
| MR grade ≥2+ (30d) | 3 | 13 | 13 | 2 | 9 | 6 |
| Device success (30d)* | 85 | 70 | 53 | 84 | 68 | 59 |
| Procedural success (30d)* | 74 | 57 | 41 | 76 | 60 | 49 |
| Mortality | ||||||
| -30 days | 6 | 10 | 18 | 8 | 12 | 22 |
| -1 year | 14 | 31 | 63 | - | - | - |
a.Yoon SH et al. Transcatheter Mitral Valve Replacement for Degenerated Bioprosthetic Valves and Failed Annuloplasty Rings. Eur Heart J. 2019
b.Guerrero M et al. Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve With Severe Mitral Annular Calcification (Valve-in-Mitral Annular Calcification) in the United States. Circ Cardiovasc Interv. 2020
*MVARC defined** Different definitions were used: Yoon at al. Obstruction: › 10 mmHg gradient, Guerrero et al. Obstruction: Hemodynamic compromise
ViV valve-in-valve, ViR valve-in-ring, ViMAC valve-in-mitral annular calcification, STS-PROM Society of Thoracic Surgeons Predicted Risk Of Mortality, LVOTO left ventricular outflow tract obstruction, 30d 30 days